The first round of negotiated prices for Medicare drugs could have larger pricing implications as state prescriptions boards (PDABs) may use the new maximum fair prices to set limits for how much manufacturers can charge for the drugs in their states. Colorado’s PDAB is one board that can consider the negotiated prices in setting payment limits and is set to consider payment limits for two of the first-round drugs. In the coming months, Colorado’s PDAB will decide whether to set...